title: Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis.
abstract: Melioidosis is caused by the environmental bacterium Burkholderia pseudomallei and can present with severe sepsis. Predisposing risk factors are present in 80% of cases. Monoclonal antibodies are increasingly prescribed for varied medical conditions. This report describes the first known case of melioidosis in a patient whose only risk factor for disease is treatment with a monoclonal antibody. Prescribers of monoclonal antibodies and other immunosuppressants should ensure that their patients are aware of the potential risk of melioidosis prior to travel and the precautions that should be taken.
authors.affiliation: Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
authors.forename: R J
authors.initials: RJ
authors.lastname: Commons
authors.forename: R
authors.initials: R
authors.lastname: Grivas
authors.forename: B J
authors.initials: BJ
authors.lastname: Currie
mesh_terms: D000068879:Adalimumab; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage*; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000276:immunology; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D016957:Burkholderia pseudomallei / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008554:Melioidosis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D008875:Middle Aged; D012307:Risk Factors; D016896:Treatment Outcome; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects
chemical_list: D000890:Anti-Infective Agents; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D019980:Amoxicillin-Potassium Clavulanate Combination; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D000068879:Adalimumab
keywords: Burkholderia pseudomallei; immunosuppression; melioidosis; monoclonal antibody; psoriatic arthritis